Exscientia Ai Ltd., A Wholly Owned Subsidiary Of Recursion Pharmaceuticals, Inc.

This study tests a new drug called GTAEXS617 in people with advanced solid tumors that have not responded to standard treatments. The goal is to check the drug's safety, how the body processes it, and whether it can shrink tumors. About 230 adults with certain cancers like lung, …

This early-stage study tests an experimental oral drug, EXS73565, in about 50 adults with relapsed or treatment-resistant B-cell cancers (like certain lymphomas and leukemias). The main goal is to check safety and find the right dose, while also looking for early signs that the d…

This early-phase study tests a new drug called EXS74539 in about 40 adults with advanced solid tumors, including lung, prostate, ovarian, and breast cancers. The main goal is to find a safe dose and check for side effects. Researchers will also watch for signs that the drug shrin…